CORPORATE ACCESS

ENGLEWOOD, CO / February 5, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced the acceptance of scientific abstracts reporting the findings...

ENGLEWOOD, CO / January 28, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs today announced the acceptance of a scientific abstract reporting the results of...

Aytu and Innovus Shareholder Meetings to Approve Merger Scheduled for February 13, 2020 ENGLEWOOD, CO & SAN DIEGO, CA / January 27, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that...

ENGLEWOOD, CO and SAN DIEGO, CA / December 24, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs and Innovus Pharmaceuticals, Inc. (OTCQB:INNV), a specialty...

ENGLEWOOD, CO / December 5, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced that MiOXSYS® will be featured in a Product Symposium at the 8th...

ENGLEWOOD, CO / December 3, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that Josh Disbrow, Chairman and Chief Executive...

Acerus Launches U.S. Specialty Sales Force; Sales Team Expansion Nearly Doubles Current Natesto Sales Force Expanded Commercial Operations Expected to Accelerate Natesto Growth in the U.S. ENGLEWOOD, CO / December 2, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a...

Provides More Than Six Million US Lives Unrestricted Access to Only FDA-Approved 12-Hour Codeine-Based Cold-Cough Syrup ENGLEWOOD, CO / November 19, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of...

ENGLEWOOD, CO / November 14, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today will provide an overview of its business, including the...

ENGLEWOOD, CO / November 11, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the hiring of Matthew Phillips as the company's...

ENGLEWOOD, CO / November 7, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the company will present its operational results...

Asset Purchase Increases Combined Company Annual Revenue to $44M, Including Previously Announced Acquisition of Innovus Pharmaceuticals Over $5 Million in Near-Term Cost Savings Expected Through Efficient Sales Force Integration and Removal of Redundant Operations...

Tuzistra XR Now Covered on Commercial Plans Covering Over 30 Million U.S. Lives U.S. Cough Cold Prescription Market is Worth in Excess of $3 Billion at Current Brand Pricing, with 30-35 Million Prescriptions Written Annually ENGLEWOOD, CO / October 21, 2019 / Aytu...

Phase IV, Investigator-Initiated Study is First to Conclusively Show that a Testosterone Replacement Therapy (TRT) Maintains Key Fertility Measures in Men with Low T Natesto Increased Serum Testosterone and Improved Hypogonadal Symptoms While Simultaneously...

Investigator-initiated, Phase IV study results will be presented today at 75th Annual American Society for Reproductive Medicine (ASRM) scientific conference ‘Late Breaking' abstract session ENGLEWOOD, CO / October 16, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU),...

Transaction increases annual revenue to $44M and is expected to accelerate time to breakeven, following recently announced acquisition of Innovus Pharmaceuticals Total upfront consideration equals 1.4x LTM revenue plus assumption of debt Triples size of Rx product...

Armistice Capital and Altium Capital jointly participated in financing ENGLEWOOD, CO / October 14, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical...

Co-Promotion Expands Physician Promotion of Aytu's Prescription Sleep Aid with Dedicated Specialty Sales Force, into Psychiatry Market, Which Accounted for Over 2.7 Million Zolpidem Tartrate Prescriptions for The Twelve Months Ending August 2019 Aytu's third announced...

Results Do Not Include September 2019 Definitive Agreement to Acquire Innovus Pharmaceuticals: Combined LTM revenues of over $31M, Diversifies product line by 10x to over 30 products ENGLEWOOD, CO / September 26, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty...

During the 12-month period ending June 2019, the U.S. prescription TRT market registered 6.9 million prescriptions, generating approximately $1.7 billion in revenue ENGLEWOOD, CO / September 24, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical...

ENGLEWOOD, CO / September 19, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that the company will present its operational results for the...

ENGLEWOOD, CO / September 17, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer, and...

Acquisition Gives Aytu Timely Entry into Growing Consumer Healthcare Market with a Portfolio of Over 30 Products that Generated $24M of Revenue During Past Four Quarters Combination Will Create Specialty Rx and Consumer Pharma Company with Revenue of $31M New...

Androcryos, South Africa's Largest Sperm Bank, First Laboratory in Africa to Offer MiOXSYS Test ENGLEWOOD, CO / September 10, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products...

Co-promotion nearly doubles Tuzistra XR sales force Poly's geographic footprint covers approximately 750,000 antitussive prescriptions annually accounting for approximately $128 million in annual revenue ENGLEWOOD, CO / September 4, 2019 / Aytu BioScience, Inc....

ZolpiMist Clinical Study Results Demonstrating Lingual Spray Delivers More Rapid Sleep Onset Compared to Tablet Form of Zolpidem Based on Efficacy Parameters and Pharmacokinetics ENGLEWOOD, CO / August 5, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty...

Natesto Spermatogenesis Study Data Readout Set for October 16, 2019 ENGLEWOOD, CO / August 1, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today...

Acerus to Launch U.S. Specialty Sales Force; Nearly Doubles Natesto Sales Force ENGLEWOOD, CO / July 30, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs,...

ENGLEWOOD, CO / July 24, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that Natesto® (testosterone nasal gel) is now on...

First Natesto Study to Demonstrate Efficacy in Severely Hypogonadal Patients ENGLEWOOD, CO / July 8, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs,...

First Clinical Data Demonstrating Predictive Power of Seminal Oxidation-Reduction Potential (ORP) as a Predictor of Fertilization When Used Prior to IVF ENGLEWOOD, CO / June 25, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on...

ENGLEWOOD, CO / June 24, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced that the MiOXSYS® male infertility test will be featured today in...

11 Abstracts Featuring MiOXSYS have been Selected for Presentation at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology ENGLEWOOD, CO / June 18, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused...

ENGLEWOOD, CO / June 12, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Natesto® has been featured on KPRC-TV, an...

ENGLEWOOD, CO / June 11, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, is set to join the Russell Microcap® Index at the conclusion of the 2019...

Initial Purchase by Beijing Dahua Sanxin Technology Development Co., Ltd. Represents First MiOXSYS Commercial Sale in China. ENGLEWOOD, CO / June 4, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel...

ENGLEWOOD, CO / May 21, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that MiOXSYS®, the company's first-in-class seminal oxidative...

Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / May 14, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today will provide an overview of its...

Live Conference Call and Webcast Scheduled for May 14, 2019, at 9:00 a.m. ET ENGLEWOOD, CO / May 7, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today...

ENGLEWOOD, Colo., March 7, 2018 -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that it has received registration in Mexico for the MiOXSYS...

ENGLEWOOD, Colo., March 6, 2018 -- Aytu BioScience, Inc. (NASDAQ: AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the closing of its previously announced...

ENGLEWOOD, Colo., March 1, 2018 -- Aytu BioScience, Inc. (NASDAQ: AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the pricing of an underwritten public offering...

ENGLEWOOD, Colo., Feb. 21, 2018 Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an update on the ongoing launch of Natesto in the U.S. Robust Natesto...

Natesto prescriptions increased 23% over previous quarter, and 317% over the same quarter last yearENGLEWOOD, Colo., Feb. 8, 2018 -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the...

Live Conference Call and Webcast Scheduled for February 8, 2018, at 4:30 p.m. ETENGLEWOOD, Colo., Feb. 1, 2018 -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology,...

Presentation on Tuesday, January 9th at 9:30 AM Pacific TimeENGLEWOOD, Colo., Jan. 2, 2018 -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that...

ENGLEWOOD, Colo., Dec. 18, 2017 -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the appointment of David A. Green as Chief Financial Officer. Mr....

ENGLEWOOD, Colo., Nov. 28, 2017 -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an update on the launch of Natesto in the U.S. Significant Natesto...

ENGLEWOOD, Colo., Nov. 9, 2017 -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an overview of its business, including the Company's operational and...

ENGLEWOOD, Colo., Nov. 7, 2017 -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the Australian Government Department of Health and Therapeutic...